A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Liu JF, Xiong N, Wenham RM, Wahner-Hendrickson A, Armstrong DK, Chan N, O'Malley DM, Lee JM, Penson RT, Cristea MC, Abbruzzese JL, Matsuo K, Olawaiye AB, Barry WT, Cheng SC, Polak M, Swisher EM, Shapiro GI, Kohn EC, Ivy SP, Matulonis UA.
Liu JF, et al. Among authors: cheng sc.
Gynecol Oncol. 2024 May 16;187:105-112. doi: 10.1016/j.ygyno.2024.05.002. Online ahead of print.
Gynecol Oncol. 2024.
PMID: 38759516